Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8805707 | 0.82 | KMT2A (0.36) | TDP1MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL28104953 | 0.79 | HTT (0.51) | MEN1KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL12548279 | 0.78 | MEN1 (0.33) | TDP1MEN1KMT2AKDM4EPOLB | |
| SCHEMBL12867885 | 0.76 | KDM4E (0.42) | TDP1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL54695 | 0.75 | KMT2A (0.54) | TDP1MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL18407151 | 0.75 | TDP1 (0.50) | TDP1MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL2851741 | 0.74 | NPSR1 (0.51) | TDP1MEN1KMT2AALDH1A1HPGD | |
| Formic Acid SCHEMBL26103549 | 0.73 | TDP1 (0.52) | TDP1MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL16769656 | 0.72 | — | — | |
| SCHEMBL38726 | 0.72 | TDP1 (0.61) | TDP1MEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110437189-A | A kind of preparation method of 5- formoxyl -2- furancarboxylic acid | UNIV ZHEJIANG NORMAL | 2019-11-12 | — | — | CN | claimed |
| CN-110408659-A | A kind of method of controlledly synthesis furancarboxylic acid | UNIV SOUTH CHINA TECH | 2019-11-05 | — | — | CN | claimed |
| CN-109721578-A | With the solvent and method of the crude product of purified by crystallisation 2,5- furandicarboxylic acid | 财团法人工业技术研究院 | 2019-05-07 | — | — | CN | claimed |
| CN-105974022-A | Method for measuring 5-hydroxymethyl furfural and derivatives of 5-hydroxymethyl furfural based on normal-phase and reversed-phase high-performance liquid chromatography | 南京林业大学 | 2016-09-28 | — | — | CN | claimed |
| CN-114773298-A | Preparation method of 2, 5-disubstituted furan compound | 中国科学院宁波材料技术与工程研究所 | 2022-07-22 | — | — | CN | disclosed |
| CN-107365287-B | A method of synthesis 2,5- furandicarboxylic acid | 中国石油化工股份有限公司 | 2019-11-15 | — | — | CN | disclosed |
| CN-110437189-A | A kind of preparation method of 5- formoxyl -2- furancarboxylic acid | UNIV ZHEJIANG NORMAL | 2019-11-12 | — | — | CN | disclosed |
| CN-110437189-A | A kind of preparation method of 5- formoxyl -2- furancarboxylic acid | UNIV ZHEJIANG NORMAL | 2019-11-12 | — | — | CN | disclosed |
| CN-110437189-A | A kind of preparation method of 5- formoxyl -2- furancarboxylic acid | UNIV ZHEJIANG NORMAL | 2019-11-12 | — | — | CN | disclosed |
| CN-110408659-A | A kind of method of controlledly synthesis furancarboxylic acid | UNIV SOUTH CHINA TECH | 2019-11-05 | — | — | CN | disclosed |
| CN-110408659-A | A kind of method of controlledly synthesis furancarboxylic acid | UNIV SOUTH CHINA TECH | 2019-11-05 | — | — | CN | disclosed |
| CN-109988792-A | A method of 5-HMFA is synthesized using D. radiodurans R1 | 南京工业大学 | 2019-07-09 | — | — | CN | disclosed |
| US-8129550-B2 | Oxidation of 5-(hydroxymethyl) furfural to 2,5 diformylfuran and subsequent decarbonylation to unsubstituted furan | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| CN-101340909-B | Method of inhibiting flt3 kinase | JANSSEN PHARMACEUTICA NV | 2012-01-11 | — | — | CN | disclosed |
| US-20110213112-A1 | OXIDATION OF 5-(HYDROXYMETHYL) FURFURAL TO 2,5 DIFORMYLFURAN AND SUBSEQUENT DECARBONYLATION TO UNSUBSTITUTED FURAN | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-09-01 | — | — | US | disclosed |
| CN-101917994-A | Use of CFMS inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer | JANSSEN PHARMACEUTICA NV | 2010-12-15 | — | — | CN | disclosed |
| CN-101610768-A | Methods of inhibiting C KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-23 | — | — | CN | disclosed |
| CN-101437514-A | Inhibidores of C-FMS cinasa | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-20 | — | — | CN | disclosed |
| CN-101340909-A | Method of inhibiting flt3 kinase | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-07 | — | — | CN | disclosed |
| CN-101267821-A | Synergistic modulation of FLT3 kinase using FLT3 inhibitors and farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213112-A1 | OXIDATION OF 5-(HYDROXYMETHYL) FURFURAL TO 2,5 DIFORMYLFURAN AND SUBSEQUENT DECARBONYLATION TO UNSUBSTITUTED FURAN | ADH5, DHPS, DOHH | TDP1 2023/4885MEN1 2505/4885KMT2A 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.